Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Placebo-controlled, Double Blind, Multi-centre Phase IIb Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF

NCT04229901 is registered in ClinicalTrials.gov with Cellaion SA as lead sponsor.

NCT NCT04229901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Placebo-controlled, Double Blind, Multi-centre Phase IIb Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF
Lead sponsor
Cellaion SA
Phase
Phase 2
Overall status
Terminated
Start date
January 21, 2020
Completion date
May 10, 2024
Enrollment
133 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

acute on chronic liver failure